Quantum Graphite Limited (ASX:QGL)

CTI BioPharma Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Selling, General & Admin	5.54	2.94	3.35	1.36	2.12	1.5
Research & Development	0.73	0.54	0.65	0.19	0.19	-
Other Operating Expenses	0.44	0.53	0.87	0.55	-0.08	-0.39
Operating Expenses	6.75	4.04	4.91	2.16	2.28	1.11
Operating Income	-6.75	-4.04	-4.91	-2.16	-2.28	-1.11
Interest Expense	-0.38	-0.28	-0.04	-0.03	-	-
Interest & Investment Income	0	0	0	0	0	0
Currency Exchange Gain (Loss)	-0.01	-0.01	0.01	0	-	-
Other Non Operating Income (Expenses)	0.01	-	-	-	-	-
EBT Excluding Unusual Items	-7.13	-4.32	-4.94	-2.18	-2.28	-1.11
Gain (Loss) on Sale of Assets	-	-	0.2	-	-	0.15
Other Unusual Items	0	-0.05	-0.42	-0.07	0.21	-
Pretax Income	-7.13	-4.37	-5.16	-2.25	-2.07	-0.96
Net Income	-7.13	-4.37	-5.16	-2.25	-2.07	-0.96
Net Income to Common	-7.13	-4.37	-5.16	-2.25	-2.07	-0.96
Shares Outstanding (Basic)	341	338	329	289	233	219
Shares Outstanding (Diluted)	341	338	329	289	233	219
Shares Change (YoY)	1.29%	2.79%	13.83%	23.62%	6.66%	7.97%
EPS (Basic)	-0.02	-0.01	-0.02	-0.01	-0.01	-0.00
EPS (Diluted)	-0.02	-0.01	-0.02	-0.01	-0.01	-0.00
Free Cash Flow	-2.34	-2.21	-4.55	-2.35	-1.2	-0.55
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.01	-0.00
EBITDA	-6.72	-4.01	-4.87	-2.1	-2.23	-1.06
D&A For EBITDA	0.03	0.03	0.03	0.06	0.05	0.06
EBIT	-6.75	-4.04	-4.91	-2.16	-2.28	-1.11

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.